跳至內容

N-氨甲醯穀氨酸

維基百科,自由的百科全書

N-氨甲醯穀氨酸
臨床資料
商品名英語Drug nomenclatureCarbaglu, Ucedane
其他名稱(S)-2-ureidopentanedioic acid
AHFS/Drugs.comMonograph
核准狀況
懷孕分級
給藥途徑By mouth
ATC碼
法律規範狀態
法律規範
藥物動力學數據
生物利用度30%
血漿蛋白結合率Undetermined
藥物代謝Partial
生物半衰期4.3 to 9.5 hours
排泄途徑Fecal (60%) and kidney (9%, unchanged)
識別資訊
  • (2S)-2-(carbamoylamino)pentanedioic acid
CAS號1188-38-1  ☒N
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.116.323 編輯維基數據鏈接
化學資訊
化學式C6H10N2O5
摩爾質量190.16 g·mol−1
3D模型(JSmol英語JSmol
  • C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
  • InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 checkY
  • Key:LCQLHJZYVOQKHU-VKHMYHEASA-N checkY

N-氨甲醯穀氨酸(英語:Carglumic acid,商品名:Carbaglu等)是一種有機化合物,分子式C6H10N2O5,用於治療高氨血症[3][6][7]

參考文獻

[編輯]
  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. 
  2. ^ Health Canada New Drug Authorizations: 2015 Highlights. Health Canada. 4 May 2016 [7 April 2024]. 
  3. ^ 3.0 3.1 Carbaglu- carglumic acid tablet. DailyMed. [9 June 2021]. 
  4. ^ Carbaglu EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021]. 
  5. ^ Ucedane EPAR. European Medicines Agency (EMA). 17 September 2018 [9 June 2021]. 
  6. ^ Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004, 145 (4): 552–4. PMID 15480384. doi:10.1016/j.jpeds.2004.06.047. 
  7. ^ Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002, 52 (6): 845–9. PMID 12447942. S2CID 24604774. doi:10.1002/ana.10406可免費查閱.